PetVivo Holdings Inc (PETV) Cotización

$PETV The studies will show dramatic benefits to the dogs, the same as horses. The granulated matrix of heparin, collagen and elastin when injected becomes sponge-like creating a lubricated environment. It also seals the synovial sac and helps the body rebuild the joint. Very different than blocking the nerve as Librela does. It solves the problem! This is why it will take over Librela’s sales!

$PETV Happy new year to this board! I believe Petv will be one of the biggest percentage gainers this year! Why? first the Company is reaping the benefit of its marketing in reaching small animal Vets of the past two years. This required investment in salesmen and several major wholesalers training! Now that ZTS will have problems they stand ready to steal all the $10’s of millions of Librela marketing to bring awareness to Spryng as the better cheaper and totally safe product. This will wake the stock up! Second, the company will complete the ability to be re-listed! I expect by the end of the first quarter and with the ZTS blow up the market cap will explode. 3) sales surging and breakeven and earnings insight for the market to discount. I am long and could trade at anytime!

As a PetVivo salesman, I’d like to discuss why Spryng is a superior choice for treating osteoarthritis in dogs and cats compared to Librela. Let’s examine the facts: Librela’s Concerning Safety Profile Librela, while marketed as an effective treatment, comes with significant risks: • The FDA received over 3,800 reports of side effects through the end of 2023 • The European Medicines Agency received more than 12,300 adverse event reports since 2021 These side effects include: • Ataxia • Seizures • Neurological issues (paresis, recumbency) • Urinary incontinence • Polyuria and polydipsia • In some cases, death or euthanasia Just three weeks ago, the FDA cited Zoetis for potentially underreporting more severe side effects, raising serious concerns about the drug’s safety profile. Problems with Nerve Growth Factor Inhibition Librela’s mechanism of action, inhibiting nerve growth factor (NGF), can lead to: • Increased risk of rapidly progressive osteoarthritis • Potential for osteonecrosis • Systemic effects throughout the body, not just in affected joints • Dramatic increase in systemic oxidative stress, particularly harmful for animals in pre-arthritis and early arthritis stages Spryng: A Superior Alternative Now, let me introduce you to Spryng, a revolutionary treatment that addresses the root cause of osteoarthritis: 1. Mechanism of Action: • Provides a shock-absorbing matrix that mimics natural cartilage • Directly addresses joint mechanics, not just masking pain 2. Safety Profile: • Demonstrated excellent safety in clinical studies • No significant adverse events reported • Localized to the injected joint, minimizing systemic effects 3. Long-lasting Effects: • A single injection can provide benefits for up to 12 months or longer • Compared to Librela’s required monthly injections 4. Cost-effective: • Approximately 50% cheaper for the customer over the course of a year 5. Natural Composition: • Made from purified, naturally-derived proteins and carbohydrates • Mimics the structure and function of natural cartilage 6. Regulatory Advantage: • Classified as a veterinary medical device, not requiring FDA premarket approval 7. Versatility: • Effective for all stages of osteoarthritis • Can be used in multiple joint locations By choosing Spryng, you’re offering your patients a safer, more effective, and cost-efficient solution for managing osteoarthritis. It’s time to move beyond simply masking pain and address the underlying cause of joint issues, providing long-term relief and improved quality of life for our furry companions.

$PETV So when the FDA realizes that ZTS deceived over 50% of the dog and cat owners or close to 30000-400000 , they will totally pull the drug in my opinion! All this info came from Perplexity Pro research and quoted from the human research done by Pfizer, jnj and numerous other major drug companies. The mechanisms are no different in dogs and cats. Just lowering the dose is wrong. It demonstrates through the impact on the redox system that it leads to accelerating the development of the damage to the joint and bone but also the mitochondrial damage. Spring has no side effects and can be used very early and at half price. I guarantee PETV’s distributors will use this info and the Vets fears of being sued as well will cause an immediate switch to Spryng. This could make Spryng a $100 million sales proxy within 2 yrs. This is $99 million of contribution earnings or over $4/ shr. Stock could be explosive.

$PETV This Librela problem is much bigger than ZTS and their analyst community is expecting. 20000 reported major dog incidents reported in the European union means that the side effects are over 10% of the injected dog and cat population. It has to be the same here! The FDA has warned the Vets and now is surveying them and will find this out. Yes ZTS is the PFE( yes their spin out) of the animal health world but even they will have to withdraw in the face of massive class action suits. The Vets have gotten use to this new source of revenue and will quickly replace it with Spryng which solves the arthritis problem not just hide it. No side effects. Thus Petv inherits ZTS $1 billion drug outlook for their FDA approved device! All that marketing money now inures to PETV’s benefit. $75 billion into $11 million!! I guess Petv runs huge or ZTS buys them for a big number, either way this is the stock of early 2025!
Bullish

Exciting update! Scot Cave is now with PetVivo Holdings, Inc. as Field Veterinary Business Development Manager. Watch $PETV! @PetVivo

PETV: delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

why bullish

Moving

Extreme caution here! Price ran up on hype of starting clinical trials for humans for OAK. The market is littered with failed attempts of companies that had far better solutions and they still failed. They will require well over $100 million for all the required pre-clinical and P1, 2 and multiple 3 trials. And the time to completion will definitely not be quick. This is a MINIMUM OF TEN YEARS. PETV has market cap of only about $30 million and they will have to raise over $100 million. what do you think will happen to the share price with that kind of dilution? Yes. . . .we will see many price drops and multiple reverse splits as the company tries to raise money. And short interests know this so I can guarantee that they will be shorting this and driving the price down and down and down. Just take a look at the record of Adam Feuerstein. He broke AMPE that had a much better OAK solution and now the shares are almost worthless after 14 years. And the CEO is one of these know it all arrogant types that is in for a ride to hell. VERY STRONG SELL IMO!

The Company’s management team in cooperation with its human advisory task force anticipates regulatory plans to be completed for new human products implementing the Biomatrix Particulate Technology in the first part of calendar year 2024. The products for human use will be manufactured by PetVivo in its state-of-the-art manufacturing facility in Edina, Minnesota, which is anticipated to be opened in the fourth quarter of 2023.

It's easy, to be honest when you don't say anything. They have an association with a really bad guy, Rich Carozza. He has been with every bad BD on the street. Imay have heard that he is under SEC and FBI investigation. Not sure what he is doing with PETV but it's never good. He is a really bad guy. Beware. IMO

Honest CEO here IMO.

$PETV Live on the Emerging Growth Conference in 30 Minutes

Registration link to interact with the company live here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167551494

$PETV Live on the Emerging Growth Conference Jan 19

Registration link to interact live with the company here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167540089

What is the strike price on the company’s warrants?

Congratulations John Lai on your growth in the markets!!! Good man!

PETV - Friday Rundown, Monday Expectations

Replay $PETV Emerging Growth Conference.

Link to the video is here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166165192

Next Conference October 13
Register Here:
https://goto.webcasts.com/starthere.jsp?ei=1487781&tp_key=e2bca7d62c&sti=twitter

Who do you want to see present?
Tell us here:
www.EmergingGrowth.com/Conference

EGC 17 Replay:
$CANB
$PBIO
$GNTW
$AWX / $AWG
$PETV
$UCASU
$CLSH
$MARK
$CYDY

$PETV Live on the Emerging Growth Conference in 30 minutes!

The Link to Register to Interact Live with the CEO's is here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334

Companies Presenting:
$UCASU
$CLSH
$MARK
$CYDY

Presenting now or Previously:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX

$PETV Emerging Growth Conference 17 Starts in 1 hour!

The Link to Register to Interact Live with the CEO's is here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334

Companies Presenting:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX
$PETV
$UCASU
$CLSH
$MARK
$CYDY

$PETV PetVivo CEO Live on the Emerging Growth Conference on September 29, 2021

Registration link here to interact Live:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166052950

Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference

$PETV Replay Emerging Growth Conference 14
Get the link
and...

Register for the next Conference on 9/1 here...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165547337

Who do you want to see present?

EGC 14 Presenters for Replay:
$NSAV - VirtuaBroker
$RYAH $RYAHF
$PETV
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD

$PETV Live on the Emerging Growth Conference in 30 minutes!

Link to watch the Conference here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165497793

Other Companies Presenting:
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD

Presented Earlier:
$NSAV
$RYAH $RYAHF

$PETV Live on the Emerging Growth Conference this Wednesday August 18, 2021.

The registration link so you can watch the live presentation is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165458105

$PETV PetVivo Congratulations on the NASDAQ Uplist! CEO Live on the Emerging Growth Conference on August 18, 2021

Registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165396738


Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference

PETV moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

$PETV PetVivo Presenting Live on the Emerging Growth Conference on August 18, 2021

Registration Link Here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165369149

Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference

1for 4 reverse.

Nasdaq?

PETV: effective Dec. 30,2020 a one for 4 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

ANOTHER RS coming. Tomorrow at the bell this ticker has a 1 for 4 RS. Hell...they just pulled a RS a year ago.

Share holders on 12/30 won't be able to sell until well into the first week of Jan, maybe later.

10,000 shares become 2500. Nice..............

Congrats to John Lai!!!

NEWS: $PETV nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants

Orlando, Florida, Oct. 20, 2020 (GLOBE NEWSWIRE) -- nScrypt is excited to announce the successful bioprinting of PetVivo ® Holdings’ biomaterial, using nScrypt’s 3D Bio-Fabrication Tool (BAT). The nScrypt BAT technology was able to easily 3D ...

Got this from PETV - nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants

New video Interview

PETV a nine for ten reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

$PETV - PetVivo Up 102% Last Week on $3 Price Target Issued 

PetVivo’s Holdings, Inc.  (PETV: OTCQB)  - CEO, John Lai, discusses the new and revolutionary treatment of osteoarthritis by administering PetVivo’s injectable product

See the video here:

PETV Daily Chart...MACD moving up..

News out --- PetVivo Holdings, Inc. Featured in New Research Update
Press Release | 09/26/2019
MINNEAPOLIS, MN, Sept. 26, 2019 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.

The updated report provides an overview of recent events, new initiatives, and the company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed at its partner site, www.GoldmanResearch.com.

Marble Arch Research notes that, “With a number of competitive advantages in the space, a deep product pipeline and IP portfolio, combined with a clever financial model, we believe that the Company can enjoy hockey-stick type sales growth in the next 2-3 years. Plus, its new technology licensing for CBD use could prove to be a sleeper and a very profitable engine for PetVivo. Our target is based upon a 5.5x sales P/S multiple, similar to its peer group, and affirmed by a Net Present Value (NPV) calculation. In our view, the current price reflects an attractive entry point.”

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of eighteen patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses called Kush® is scheduled for launch later this fiscal year.

The Company recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market. The Company will also be seeking additional licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:
John Lai
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216

I found this on their website...very interesting.

One Injection Restored Mobility in Their Lives for Years – $PETV

https://petvivo.com/

Interesting Development.

Emerald Organic Products, Inc. (EMOR) Announces Exclusive Licensing Agreement With PetVivo Holdings Inc. (PETV).

“In the right hands, this product has the potential to revolutionize the vitamin and CBD market place and we are confident we found the right team partner in Emerald.”

http://marijuanastockreview.com/emerald-organic-products-inc-emor-announces-exclusive-licensing-agreement-with-petvivo-holdings-inc-petv/

Anyone have an idea if PETCO joint goop is viable and soon to report initial sales?

The term someone shed a light down the crack.

Wow.

The term "fallen between the cracks" comes to mind. Studying now.

Percentage drop appears like a typical toxic unwinding, but there's no volume so doubt that was the cause.

MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- OTCPINK: PETV PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is pleased to announce the addition of Mr. Michael Haider and Mr. Joel Hapke.

Michael Haider has over 40 years of medical business, finance and management experience, most recently as Co-Founder and CEO of CytoMedical Design Group LLC, a company focused on blood-based stem cell research. Haider was President and CEO of BioE LLC, BioE, Inc. and he was President and owner of Kodiak Restoration, a dental and medical equipment service company; president and co-founder of PulseTrend, Inc., a maker of ambulatory blood pressure devices; and vice president and CFO of PPT Vision, a producer of machine vision technologies. Prior to these endeavors, Haider held a variety of positions in corporate finance at Medtronic, Inc., a leading provider of medical devices. Recent Honors: He was named one of Twin Cities-based Finance and Commerce’s “Innovators of The Year” in 2003. In 2006 Minnesota Tekne Award, Emerging Biotechnology Company category and Twin Cities Business, 2007 Biosciences Success Stories. 2009 to current a member of the National Marrow Foundation (“Be the Match”) New Technology Council, since 2007 to current an annual presenter of stem cell business strategies to the University of Minnesota School of Pharmacy.

Mr. Haider commented, “I am looking forward to working with the PetVivo team toward implementing PetVivo’s vision and exciting technology toward improved patient outcomes in veterinary and future human therapies. “

Mr. Joel Hapke has over 30 years of combined experience in clinical laboratory science, medical device and diagnostic assay development. Joel has been with CytoMedical Design, LLC and BioE, Inc. for the past 18 years as the Manager of Manufacturing, Analytical and Process Engineering. Prior to coming to BioE and CytoMedical, Joel was employed by QuanTech Ltd. As the Systems Integration Coordinator, working with both engineering and chemistry personnel to develop a clinical assay platform utilizing Surface Plasmon Resonance (SPR) for a Point of Care medical device.

“The addition of Mr. Haider and Joel Hapke, working alongside our current staff in our manufacturing and research area, gives PetVivo an ability for testing, revising and innovation with little outside contracting of services. Our intension is to continue on this path, creating better manufacturing standards and efficiencies along with expanding the use of our current products.” Stated Wes Hayne, CEO.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s

lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: info1@petvivo.com

Main: 962-405-6216

Direct: (763) 443-7272

$PETV
Good morning Murdoc
Ready to make your cash?!

$$$$

GM PETV

PETV owns a bunch of patents and from 10q for period ending 12/31/17 they only have/had? one convertible note for $110k and $557k cash on hand

https://backend.otcmarkets.com/otcapi/company/sec-filings/12706882/content/html

http://petvivo.com/patents/

Nice catch Hippo! Great to see you

PETV can break out easy.

19,189,748 OS a/o 4/30/18 
1,355,182 Float a/o 4/30/18 

Insiders holding vast majority of the issued shares